Ellevest Inc’s Lifecore Biomedical LFCR Stock Holding History

Ellevest Inc’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-294	Closed	-$1.91K	–	1994
2022 Q4	$1.91K	Buy	+294	New	+$2.42K	﹤0.01%	1400

Other funds holding LFCR

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CSC

Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

VWA

Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

Ellevest Inc's LFCR Position: Q1 2023 in Review

Ellevest Inc sold out of Lifecore Biomedical (LFCR) in Q1 2023, closing a stake of 294 shares — an estimated $1.91K sold.

Ellevest Inc first reported a position in LFCR in Q4 2022 and held it in 1 quarter. The position peaked at $1.91K in Q4 2022. 82 funds tracked by Wall St. Rank hold LFCR as of Q1 2023.

Ellevest Inc reported no remaining Lifecore Biomedical position as of Q1 2023 after selling out during the quarter.
Ellevest Inc sold 294 Lifecore Biomedical shares in Q1 2023, an estimated $1.91K.
Ellevest Inc first reported a position in Lifecore Biomedical in Q4 2022 and held it in 1 quarter.
Ellevest Inc's Lifecore Biomedical position peaked at $1.91K in Q4 2022.
82 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2023.

Based on Ellevest Inc's 13F filing for Q1 2023, filed 4 May 2023.